Qsymia Diet Pills Are Now FDA Approved

News, Pharmacy News, Prescription Weight Loss Medication 2 Comments , , , , , ,
Vivus, Inc. Qsymia Diet Pills

You’ve more than likely already heard, but if not, on July 17th, 2012, Qsymia (a combination of Phentermine and Topiramate), also previously known as Qnexa was approved by the FDA.

So what does this mean for consumers?

Well basically, you now have access to this new diet drug through a prescription provided by your doctor.

Pronounced kyoo-sim-EE-uh, it is a pill that helps obese patients drop some pounds with the use of the Phentermine weight loss stimulant as well as an extended-release anti-seizure drug called Topiramate. So far we are seeing some sources advising to stay away from the pill all together as it may come with some very serious side effects. For example, the director of Consumer Report Health Ratings Center, John Santa, M.D., was quoted on the following:

This drug should only be used in the confines of a research trial in which consumers have been fully informed of its risks and benefits and, someone is responsible for the complications that occur. All the rest of us should wait until we know a lot more about its safety.
–John Santa, M.D.

These words alone are enough to make any think twice about jumping on this new lab concoction. As of right now, Qsymia is limited to a select few of pharmacies that are certified and in agreement to a mitigation and risk eval. strategy, also known as R.E.M.S.. Now, as this seems a little like they are jumping the gun, Vivus, the manufacturer has evaluated the drug by conducting two placebo controlled (randomized) trials consisting of a whopping 3,700 patients who were both diagnosed as obese and overweight. In addition, these participants didn’t have any treatments conducted on weight related conditions for up to a year. And as with most weight loss prescriptions administered, they were given a physical regimen and reduced calorie diet to follow.

Results from the two treatments over the course of one year showed that about 69% and 62% of participants walked away (at the very least) with about 5% less body weight. These results were from the recommended and highest daily doses of Qsymia (15mg Phen. and 92mg Top.) in comparison to those treated with placebos.

Long-Term Monitoring

According to the FDA Press Announcement, Vivus, Inc. of Mountain View, CA has been required to conduct cardiovascular analysis that are long-term to determine the effects of Qsymia in regards to stokes and heart attacks. The company is also required to conduct nine other postmarketing requirements.

The most commonly reported side effects are:

  • Dizziness
  • Paresthesia
  • Insomnia
  • Dry Mouth
  • Constipation, and
  • Altered Taste

Have you had an experience with Qsymia or know someone who has? If so, we would like to hear from you. Share you story with us an others by leaving a comment below.

Disclaimer: The information found throughout this website is not provided by us as a source of information that is meant to replace consultation from a licensed medical professional. Instead, please consider this information to be of entertainment only. To continue to provide our visitors with a free service and maintain this website up to date, we at times, may collect payment on a commission basis for various products that are sold throughout this website, payments from our partner's sponsored ads, and various promotional offers. All editorial reviews are unbiased and are solely the views of the editor and based off the experiences of the author.